The groundbreaking rise of Viagra has firmly established as a benchmark of pharmaceutical success, yet its future within the broader market now triggers questions about potential returns check here . Copycat versions are eroding exclusivity , leading to concerns that investing in companies closely tied to Viagra's previous position could be a probl